Otonomy saw its share price plummet by nearly 18% in after-hours trading on 21 May after it announced that its investigational treatment OTO-104 for Ménière's disease had failed a Phase IIb trial. That a range of secondary endpoints were met and the company's decision to move it into Phase III based on the data evidently failed to settle investors' nerves.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?